Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Samsung Seeks Third Anti-TNF Biosimilar Launch In Europe

Executive Summary

After receiving regulatory approvals in Europe for its biosimilar versions of etanercept and infliximab earlier this year, South Korea's Samsung Bioepis is now looking to add adalimumab to it and partner Biogen’s growing portfolio.


Related Content

Boehringer Ingelheim Throws Its Humira Biosimilar Hat Into The Ring
Samsung Enters Oncology as Trastuzumab Accepted For EU Review
LG Restructuring Ups Group Emphasis On ‘Red Biotech’
J&J Thinks It Can Win Over Biosimilar Competition
'Uncomfortable' Panel Backs Amgen Biosimilar, But Uphill Battle To Sway Docs, Public
Samsung Bioepis Taps Infliximab As Its US Biosimilar Pioneer
Samsung Bioepis's Etanercept Biosimilar To Be Rolled Out In Europe


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts